Leucovorin + 5-Fluorouracil + Aldoxorubicin HCl + nab-Paclitaxel + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 + Avelumab + ALT-803 + haNK + Cyclophosphamide + Doxorubicin HCL + paclitaxel
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer (TNBC)
Conditions
Triple Negative Breast Cancer (TNBC)
Trial Timeline
Sep 1, 2018 → Feb 9, 2022
NCT ID
NCT03554109About Leucovorin + 5-Fluorouracil + Aldoxorubicin HCl + nab-Paclitaxel + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 + Avelumab + ALT-803 + haNK + Cyclophosphamide + Doxorubicin HCL + paclitaxel
Leucovorin + 5-Fluorouracil + Aldoxorubicin HCl + nab-Paclitaxel + ETBX-011 + ETBX-051 + ETBX-061 + GI-4000 + GI-6207 + GI-6301 + Avelumab + ALT-803 + haNK + Cyclophosphamide + Doxorubicin HCL + paclitaxel is a phase 2 stage product being developed by ImmunityBio for Triple Negative Breast Cancer (TNBC). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03554109. Target conditions include Triple Negative Breast Cancer (TNBC).
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer (TNBC) were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03554109 | Phase 2 | Withdrawn |
Competing Products
20 competing products in Triple Negative Breast Cancer (TNBC)